Zealand Pharma announces that the first participant has been enrolled in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity. The Phase 2b ZUPREME-1 trial is designed ...

Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.

Petrelintide is undergoing phase two trials, with plans for phase three currently underway. Steensberg said that the companies hope to bring the product to market by 2030.

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug.

Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1050 ET – Zealand Pharma’s petrelintide shot has the ...

Danish biotech company Zealand Pharma A/S ZLDPF has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial of its weight management drug, petrelintide. The trial ...

Petrelintide was "judged to be safe and well tolerated at all dose levels," and the results provided "robust support" for its potential as an alternative to GLP-1 receptor agonist-based therapies ...

Zealand Pharma's petrelintide shot has the potential to reduce body weight by more than 15% in longer trials, analysts from Jefferies write in a note following data from a 16-week trial that ...

Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that ...